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ABSTRACT 
Introduction:  Antimicrobial resistance is one of the most severe health threats globally.  
([WHQGHGVSHFWUXPȕ-lactamases (ESBLs) are enzymes produced by a variety of gram-
negative bacteria, which lead to an increase in resistance to commonly used antibiotics and 
are associated with higher morbidity and mortality. Objectives: Assess the prescribing 
practices prior to, and after, positive ESBL producing microbiology cultures in an adult ICU 
setting, according to sensitivity reports obtained from the clinical laboratories from January 
2013 until January 2014. Subsequently use the findings to guide future practice. 
Method:  Retrospective study at a private hospital in Pretoria, Gauteng Province. All adult 
patients older than 18 years of age that were admitted to either the MICU or the TICU with a 
positive producing ESBL culture during their hospitalised stay were assessed.  Results:  
During the study period, 39 patients in the MICU and TICU had positive ESBL microbiology 
results.  The majority of positive ESBL results were due to Klebsiella pneumonia isolates.  
Antibiotics prescribed post ESBL positive culture were appropriate according to the 
sensitivity report in 64% of patients.  22 patients survived and 17 patients died.  All the 
patients that died were on invasive ventilatory support. Conclusion:  Clinically it appears as if 
patients who received appropriate therapy according to the microbiology results showed a 
better clinical outcome than those with inappropriate therapy. This underlines the importance 
of appropriate prescribing practices in combination with co-morbid conditions.   Invasive 
ventilatory support can be identified as a clear risk for contracting an infection due to an 
ESBL producing organism.   
 
1. INTRODUCTION 
 
Antimicrobial resistance (AMR) is one of the most severe health threats, both globally and in 
South Africa [1]. This is illustrated by the World Health Assembly in 2015 adopting a global 
action plan on AMR which underlines a global consensus that AMR poses a profound threat 
[2].  This is illustrated in South Africa and among sub-Sahara African countries with efforts 
to document current antimicrobial utilization patterns, investigate antimicrobial stewardship 
programmes and assess antimicrobial utilization against current guidance [3-8]. Infections 
from resistant bacteria are becoming more common, and some pathogens have even become 
resistant to multiple classes of antibiotics.  Extended-VSHFWUXPȕ-lactamase (ESBL) 
producing bacteria have become recognized as a challenge in South Africa with an extremely 
high prevalence of ESBL producing organisms.  The ESBL producing organism rate for 
Klebsiella pneumoniae cultured from complicated intra-abdominal infections in private 
hospitals in South Africa is 41.2%, and that for bacteraemic isolates in the public sector 
varies between 55 to 74% [9]. 
 
AMR occurs when bacteria change in a way that eliminates or reduces the effectiveness of 
the drugs available to treat them [10].  Our ability to treat infectious diseases and to manage 
infectious complications in vulnerable patients is undermined by the loss of effective 
antibiotics leading to increased morbidity, mortality and costs [1,11]. 
 
([WHQGHGVSHFWUXPȕ-lactamase (ESBLs) are enzymes produced by a variety of gram-
negative bacteria which leads to an increase in resistance to commonly used antibiotics.  
Infections caused by such enzyme-producing organisms are associated with higher morbidity 
and mortality [2]. The increasing prevalence rates of ESBL producing organisms worldwide, 
coupled with the lack of development of new antibiotics in the short term, symbolizes an 
appreciable danger to public health [12].  According to the latest data in the United States, 
patients with bloodstream infections caused by ESBL producing Enterobacteriaceae have a 
57% higher mortality than those with bloodstream infections caused by a non ESBL 
producing strain [11]. 
 
According to Coetzee and Brink, the utilisation of ertapenem, meropenem and, imipenem in 
the private sector in South Africa more than doubled between January 2009 and June 2011 
[13].   Whilst it is recognized that the carbapenems are the cornerstone of therapy for patients 
with serious infections caused by ESBL producing organisms, the high prevalence of ESBL 
amongst bacteraemic pathogens places a tremendous strain on the use of these agents both as 
empiric therapy as well as directed therapy.  Not only does the increasing consumption of the 
carbapenems create an ideal environment for the development of carbapenem resistance 
among the Enterobactericeae, carbapenem use has been shown to be a risk factor for 
subsequent infections with ESBL producing organisms through selective pressure.  
Inappropriate use is selecting for the very resistance that the class is being used for [13].  In 
the public health care sector in South Africa, K. pneumoniae showed a higher rate of 
resistance than E. coli bacteraemia [14], which is also a concern.   
 
In view of these concerns, we wanted to investigate the situation within the ICU of a leading 
large private hospital in South Africa to improve the future care of these patients. This is 
because in the beginning of 2013, a significant increase in the number of ESBL producing 
isolates was noticed, with 18 patients producing ESBL positive cultures in one month.  
Consequently, this study aimed to evaluate prescribing practices among patients in an 
intensive care unit (ICU) setting prior to and post positive ESBL producing organisms, 
according to the positive microbiology results. Subsequently, use the findings to improve 
future prescribing if pertinent.  
 
2. METHODS 
 
2.1 Study design and population 
This retrospective, quantitative study was performed at a private hospital in Pretoria, Gauteng 
Province, South Africa, which is the largest private hospital in South Africa with 470 beds. 
The multi- and trauma ICU in this private hospital contains 29 beds, with the multi-intensive 
care unit (MICU) and Trauma intensive care unit (TICU) having 21 beds and eight beds 
respectively. The ICU has an average of four patients per month with positive ESBL 
producing organisms.  The study followed an epidemiological observational design.  
 
2.2 Data collection and analysis 
Purposive sampling was used for all consecutive patient files of adult patients older than 18 
years that were admitted to these two units that had cultured positive ESBL producing 
organisms during their hospitalised stay from January 2013 until January 2014.  Since the 
study was a census, the data from all the files during the study period were recorded on a 
form designed according to recommendations by Gregory and Radovinsky [15].  The data 
from the patient files were collected, managed, and analysed using the IBM Statistical 
Package for Social Sciences Statistics® (SPSS) programme.  Descriptive statistics were used 
to analyse data for prescribing patterns in the presence of ESBL producing organism.  This 
was followed by determining the antibiotics that were prescribed prior to the diagnosis of 
ESBL producing organism and after ESBL producing organisms were diagnosed.   
 
Antibiotic use would be considered appropriate when the antibiotic prescribed was sensitive 
according to the microbiology result obtained from the laboratory data. The total daily 
consumption (TDC) refers to the antimicrobial dose that the patients received, with this 
methodology used in studies to monitor antimicrobial utilization [15,16].  Defined daily doses 
(DDD) were also calculated with DDDs being the assumed average maintenance dose per 
day for a medicine used for its main indication in adults according to the World Health 
Organisation (WHO) [2,15,17,18].  
 
The Fischer exact test was used to test the asVRFLDWLRQEHWZHHQYDULDEOHVVXFKDVSDWLHQWV¶
gender, age, diagnosed condition and length of stay in the adult ICU and the antibiotic 
prescription patterns. The Pearson correlation test was used to determine the statistical 
correlation between the combined age/co-morbid score and the relative risk of death ratio 
according to the Age-Adjusted Charlson Comorbidity index (AACI). 
 
2.3 Risk factors for infection due to ESBL producing organisms 
Each patient was included as a case only once.  If an ESBL producing organism was isolated 
RQPXOWLSOHRFFDVLRQVRQO\WKH¿UVWHSLVRGHRILQIHFWLRQZDVUHYLHZHG+RVSLWDODFTXLUHG
LQIHFWLRQVDUHGH¿QHGE\WKH&HQWHUVRI'LVHDVH&RQWURO&'&DVDQLQIHFWion that occurred 
>48hours after admission to the hospital, infection up to 3 days after discharge and/or 
infection up to 30 days after an operation [19]. 
 
The presence of a central venous catheter, urinary catheter, or mechanical ventilation was 
also assessed.  Finally, all antimicrobial therapy that was administered prior- and post to 
positive ESBL producing cultures were documented.  The presence of the following 
comorbid conditions was also documented: malignancy, diabetes mellitus, renal 
LQVXI¿FLHQF\HIV infection and neutropenia [20]. 
 
Several instruments have been developed to assess the extent of co-morbidity and grade the 
degree of comorbid burdens using ordinal scales.  One of the most widely applied is the 
Charlson Comorbidity Index (CCI), which has been extensively used to evaluate the impact 
of comorbidity in a variety of medical conditions.  The CCI was developed in 1987 and is a 
SURJQRVWLFWD[RQRP\WKDWZDVLQLWLDOO\GHYHORSHGWRDFFRXQWIRUWKHLQÀXHQFHRIDSDWLHQWV¶
adverse medical conditions in longitudinal studies and has been validated in many clinical 
settings [21,22]. This index is calculated by the summation of weight scores for 19 medical 
conditions and high scores were found to be associated with poorer prognosis [21,22].  
 
Age has also been determined to be associated with overall survival, this was the CCI 
modified by Charlson et al. in 1994 [23].  This modification called Age-Adjusted Charlson 
Comorbidity index (AACI) includes the age of the patient as a correction variable of the final 
score of the Charlson index.  Peterson et al. UHSRUWHGWKDWHDFKGHFDGHRIDJH\HDUVLV
equivalent to a 1-point increase in comorbidity (i.e. 50±59 years=1 point; 60±69 years=2 
SRLQWV>@7KH$$&,ZDVXVHGWRDVVHVVWKHSDWLHQW¶VHVWLPDWHGUHlative risk of death as 
only two patients in this study were younger than 50 years of age. The ACCI score was 
calculated for these patients and were dichotomized into four groups as recommended by 
Yang et al., i.e. having either low comorbidity (CCI = 0-1), mild comorbidity (CCI = 2-3), 
moderate comorbidity (CCI = 4±RUVHYHUHFRPRUELGLW\&&,>@ 
 
2.4 Role of ESBL-resistance in outcomes 
To evaluate the effect of infections due to ESBL producing organisms on clinical outcomes, 
the following outcomes were assessed: clinical outcome, mortality, duration of ICU stay and 
ventilation status.  The antimicrobial exposures before and after the positive ESBL producing 
organisms were cultured were also assessed.  
 
2.5 Microbiological methods 
Clinical samples were processed according to standard microbiological procedures. Bacterial 
isolates were identified with the Bruker MALDI Biotyper. Antibiotic susceptibility testing 
was performed using the Vitek 2 (bioMerieux, Johannesburg, South Africa), and interpreted 
according to the criteria of the 2013 Clinical and Laboratory Standards Institute (CLSI). K. 
pneumoniae and E. coli isolates were suspected of ESBL-SURGXFWLRQLIWKH0,&ZDV
µg/mL for ceftazidime, cefotaxime or ceftriaxone [26].  Such isolates were subjected to a 
phenotypic confirmatory test, performed by incubating the isolates with disks containing 30 
µg of cefotaxime and ceftazidime, with and without clavulanic acid (10 µg; Oxoid Ltd, 
Basingstoke, UK). The zone of inhibition was measured after 16-18 hours incubation, and an 
LQFUHDVHRI-mm in a zone diameter of either agent tested in combination with clavulanic 
acid vs the zone of the diameter when tested alone was considered to be positive for ESBL-
production.  
 
There are no CLSI criteria for confirmation of ESBL-production in Enterobacter spp. ESBLs 
are more difficult to detect in these genera that have inducible AmpC chromosomal enzymes, 
as these enzymes can be induced by clavulanic acid, and then hydrolyse the indicator 
cephalosSRULQ&HIHSLPHLVKRZHYHUDSRRUVXEVWUDWHIRU$PS&ȕ-lactamases. In 
Enterobacter VSSZLWK0,&VRIJP/IRUFHIRWD[LPHRUFHIWD]LGLPH(6%/SURGXFWLRQ
was suspected. We performed a double disk potentiation test between a cefepime disk and an 
adjacent amoxicillin-clavulanate disk on these isolates. This test is performed by placing a 
cefepime disk (30 µg) 15 mm (edge-to-edge) from a disk containing amoxicillin-clavulanate 
(20µg/10µg) [27]. 
 
2.6 Ethical considerations 
Ethical approval was obtained from the University of Limpopo - Medunsa Campus (Number 
MREC/H/227/2014: PG) and from the research operations committee of the private hospital 
were the study was conducted ± (Number UNIV-2014-0050). 
 
Participant consent was not obtained for this study.  This study was considered as an 
epidemiological observation study.  Participant personal information was only used to match 
WKHODERUDWRU\UHSRUWREWDLQHGIURPWKHODERUDWRU\GDWDVHW2QFHWKLVZDVGRQHWKHSDWLHQW¶V
personal data was anonymised and stored in a locked cupboard.  
 
3. RESULTS 
 
3.1 Study population and socio-demographic characteristics 
During the study period, 39 patients had positive ESBL producing isolates.  Of these, more 
than 70% were male (Table 1). Respiratory distress was the initial admitting diagnosis for 
41% of patients, with the mean age of patients being 62 years, with only two patients younger 
than 50 years. 36 patients received antibiotics prior to the positive ESBL producing 
organisms being cultured (92.3%) and the remaining three patients (7.7%) only received 
antibiotics after the positive ESBL producing organisms were cultured.  Infections for 36 
patients (92.3%) were classified as hospital-acquired infections and three patients (7.7%) as 
community acquired infection. 
 
Table 1 provides an overview of the baseline characteristics for the patients.  Most patients 
were male (72%).   
 
The sources where the positive cultures were principally from sputum (56%), followed by 
urine (23%) and blood cultures (15%) (Table 1). The majority of positive ESBL producing 
isolates were due to Klebsiella pneumoniae isolates (79%). 
 
  
Table 1: Baseline demographic and study characteristic information  
 
Data Characteristics No (%) of Patients (IQR) 
Demographic Data   
Total Patients 39 (100%) 
Male  29 (72%) 
Female 11 (28%) 
Age(years), Median (IQR) 62.35  (24 ± 92) 
   
LOS in ICU (days) 22.15 (2 ± 63) 
Clinical Data   
Admission Diagnosis  n=39 
Intestinal obstruction 5 (13%) 
Heart failure 1 (3%) 
Malignant neoplasma 2 (5%) 
Pulmonary problems 4 (10%) 
Respiratory distress 16 (41%) 
Sepsis 5 (13%) 
Trauma 6 (15%) 
UTI  1 (3%) 
ICU     
MICU 22 (56.4%) 
TICU 17 (43.6%) 
Charlson score, median (IQR) 5 (3-8) 
Community acquired infection 
(CAI) 3 (7.7%) 
Hospital associated infection (HAI) 
 
36 (92.3%) 
Origin of the infection   
Source of culture n=39 
Blood  6 (15%) 
Lung Tissue 1 (3%) 
Sputum 22 (56%) 
Duodenal Swab 1 (3%) 
Urine 9 (23%) 
Microbiology data n=39 
Citrobacter koseri.  1 (3%) 
Escherichia coli  4 (10%) 
Enterobacter cloacae  2 (5%) 
Enterobacter aerogenes  1 (3%) 
Klebsiella pneumoniae 31 (79%) 
 
  
3.2 Comorbidity index  
38.5% of patients had severe ACCI scores (Table 2), followed by moderate (25.6%) and mild 
(20.5%) (Table 2). Table 2 also categorises the relative risk of death ratio (RR) in relation to 
ACCI. 
 
Table 2: Age Adjusted Charlson Comorbidity index and clinical outcome (n=39) 
 
COMBINED 
AGE/CO-
MORBID 
SCORE 
AMOUNT 
N=39 
PERCENTAGE 
N=39 
RELATIVE 
RISK OF 
DEATH 
CLINICAL OUTCOME 
Percentage (n=39) 
SURVIVED DIED 
0 - 1 6 15.4% 0-1.45 100 0 
2 - 3. 8  20.5% 2.10-3.40 87.5 12.5 
4 - 6. 10 25.6% 4.40-9.23 70 30 
>6 15 38.5% 9.23-19.37 13.3 86.7 
 
The clinical outcome of the sample population corresponds with the prediction calculated by 
the AACI. According to Pearson Correlation there is a statically correlation of 0.01 between 
the combined age/co-morbid score and the relative risk of death ratio, which highlights the 
importance of co-morbid conditions in critical ill patients.   
 
3.3 Prescribing patterns  
In this study, 91 different antimicrobials were prescribed for 39 patients prior to the positive 
ESBL producing organisms being cultured; consequently, each patient received on average 
2.3 different antibiotics.  The first antimicrobials that the patients received were as follows: 
WZHQW\RQHSDWLHQWVUHFHLYHGRWKHUȕ-lactam antibiotics as empiric therapy, seven 
patients (18%) received fluoroquinolones, three (8%) patients received a carbapenem, with 
additional antimicrobials contained in Table 3.  Eight patients received one antimicrobial 
agent before positive ESBL producing organisms were isolated, with others receiving more 
(Table 4).   
 
  
Table 3 ± Details of the first antimicrobials patients received 
 
Number of 
patients (N=39) 
Antimicrobial received and ATC 
code 
Percentage 
21 ɴ-lactam (J01C, J01DB to DE) 54% 
7 Fluoroquinolones (J01MA) 18% 
3 Carbapenem (J01DH) 8% 
2 Tetracyclines (tigecycline) J01AA 5% 
1 Aminoglycosides (J01G) 3% 
1 
Imidazole derivatives (J01XD01) 
(Metronidazole) 
3% 
1 Other bacterials J01XX (Linezolid) 3% 
 Others 6% 
 
Table 4 ± Number of antibiotics patients received before positive ESBL organisms were 
isolated 
 
Number of patients (N=39) 
Number of antibiotics prior to ESBL 
isolate 
10 2 
8 1 
8 3 
8 4 
3 5 
2 0 
  
3.4 $SSURSULDWHXVHRIDQWLELRWLF¶VSRVWSRVLWLYH(6%/SURGXFLQJFXOWXUH 
The prescribing practices post positive ESBL producing organisms being cultured are 
summarised in Table 5. 
 
  
Table 5: Prescribing practices after positive ESBL producing culture 
 
Cultures obtained  
(n= 39) 
Sensitivity 
Yes/No/Not 
reported 
(NR) 
Initial Prescribed 
therapy (frequency) 
(and ATC code) 
TDC (g) DDD 
Appropriate 
Prescribing 
Yes/No/Not 
reported (NR) 
Blood (6) 
K.pneumoniae (5) Yes Doripenem (2) (J01DH04) 3 1.5 Yes 
  Yes Ertapenem (1) (J01DH03) 1 1 Yes 
  Yes Meropenem (1) (J01DH02) 6 3 Yes 
  NR Piperacillin/Tazobactam (1) (J01RA01) 13.5 14 NR 
E. cloacae (1) Yes Imipenem (1) (J01DH) 4 2 Yes 
Sputum (22) 
K.pneumoniae (18) Yes Cefepime (2) (J01DE01) 4 2 No 
  Yes Ceftriaxone (1) (J01DD04) 2 2 No 
  Yes Ciprofloxacin (1) (J01MA02) 0.8 0.5 No 
  Yes Doripenem (2) (J01DH04) 2.25 1.5 Yes 
  Yes Ertapenem (2) (J01DH03) 2 1 Yes 
  Yes Imipenem (4) (J01DH) 2.5 2 Yes 
  Yes Meropenem (4) (J01DH02) 4.5 3 Yes 
  Yes Moxifloxacin (1) (J01MA14) 0.4 0.4 No 
  NR Tigecycline (1) (J01AA12) 0.2 0.1 NR 
No AB received (1)            
C. Koseri (1) Yes Meropenem (1) (J01DH02) 3 3 Yes 
E. aerogenes(1) Yes Amikacin (1) (J01GB06) 1 1 Yes 
E. Coli (1) Yes Cefepime (1) (J01DE01) 6 2 No 
Duodenal Swab (1) 
K.pneumonia (1) Yes Doripenem (1) (J01DH04) 3 1.5 Yes 
Lung Tissue (1) 
K.pneumonia (1) Yes Cefepime (1) (J01DE01) 3 2 NR 
Urine(9) 
Ent.cloacae (1) Yes Amoxicillin (1) (J01CA04) 2 1 No 
E. Coli (3) Yes Ciprofloxacin (1) (J01MA02) 0.8 0.5 No 
  Yes Doripenem (1) (J01DH04) 3 1.5 Yes 
  Yes Meropenem (1) (J01DH02) 4 3 Yes 
K.pneumonia (5)  Yes Cefepime (1)  (J01DE01) 3 2 No 
  Yes Ertapenem (1) (J01DH03) 2 1 Yes 
  Yes Tigecycline (2) (J01AA12) 0.2 0.1 Yes 
  NR Vancomycin (1) (J01XA01) 2 2 NR 
            
TDC = Total daily consumption; DDD = Defined daily dose; NR = not reported  
 
The majority (64%) of all antibiotics prescribed post positive ESBL producing organism were 
appropriate according to the sensitivity report.  Antibiotics were prescribed to nine patients 
(23%) despite resistance to the said antibiotics on the culture reports.  One (3%) isolate  was 
not treated as the patient passed away before the antibiotic was started.  There was no 
sensitivity results available for four (10%) of the antibiotics prescribed after the positive 
culture.  
 
3.5 Sensitivity and clinical outcome 
Most (95%) of the ESBL producing organisms isolated in the 39 patients during the study 
period were sensitive to the carbapenem antibiotics.  One E. aerogenes sputum isolate was 
only sensitive to imipenem, and one K. pneumonia blood isolate showed resistance to 
imipenem.  
 
Twenty two (56%) patients survived and 17 (44%) patients died. It is clinically significant to 
note, however, that of the survivors, 32 % (n = 7) received inappropriate antibiotics.  Of the 
17 patients who died, eight (47%) received appropriate therapy, four (23%) received 
inappropriate therapy and there were no sensitivity reported for four (23%) isolates and one 
patient (6%) did not receive any antibiotics because he passed away before antimicrobial 
therapy could be started. The difference between those survivors who received appropriate 
therapy vs those who did not was not statistically significant (p=0.209) (Table 6).   
 
  
Table 6: Clinical Outcomes for patients as compared to appropriate vs inappropriate therapy 
received 
 
Clinical 
Outcome of 
Patients (N = 
39 and %s) 
Appropriate 
Therapy 
Received 
Inappropriate 
Therapy 
Received 
Other Fischer Exact 
Test 
Sensitivity 
reports 
not done 
Antibiotics 
Not 
Received 
Survived (n 
= 22) - 
56.4% 
15 (68 %) 7 (32 %) - - 
p=
0.
20
9 
 
Deceased (n 
= 17) - 
43.6% 
8 (47 %) 4 (23 %) 4 (24 %) 1 (6 %) 
 
4. DISCUSSION 
 
ESBL producing organisms were most frequent in patients aged between 51 to 60 years, 
similar to the findings of Dey et al [28].   
 
The mean length of stay in the ICU in our study was 22.15 days (range 2 to 63 days ± Table 
ZLWK,&8VWD\NQRZQWRLQFUHDVHWKHSDWLHQWV¶ULVNRIFRQWUDFWLQJLQIHFWLRQVFDXVHGE\
ESBL producing organisms [29].  According to a study conducted by Kramer and 
Zimmerman [30], there are distinct differences between patients with an ICU stay < 5 days 
YHUVXVWKRVHZLWKDQ,&8VWD\GD\V3DWLHQWVZLWKDQ,&8VWD\GD\VKDGVLJQLILFDQWO\
higher severity of illness, frequency of mechanical ventilation, ICU readmission and 
HPHUJHQF\VXUJHU\3DWLHQWVZLWKDQ,&8VWD\GD\VDFFRXQWHGIRURI all admissions 
but 63% of total ICU days; and their outcomes were uniformly poorer [30].  In this study, 
90% of patients were in the ICU for longer than five days. 
 
Of the 39 patients with ESBL producing organisms, 31 (79%) had infections due to K. 
pneumoniae and four (10%) were due to E. coli.  Most isolates were cultured out of the 
respiratory tract (56%) followed by the urinary tract (23%).  The results seem to correspond 
to global findings where K. pneumoniae and E. coli remain the dominant ESBL producing 
organisms [31].  
 
In this study population, 36 patients (92%) were on invasive ventilatory support and only 
three patients were on non-invasive ventilatory support.  This might also play an important 
role regarding the acquisition of an ESBL producing infection with the introduction of 
invasive devices. Twenty two patients survived (56%) and 17 patients died (44%).  All the 
patients that died were on invasive ventilatory support.  According to Kritsotakis et al, non-
antibiotic risk factors for carbapenem sensitive ESBL producing K. pneumonia organisms 
included invasive ventilator support, central vascular catheterization, urinary catheterization 
and tracheostomy [32]. 
 
The relatively high ACCI index, the ventilation status of the patients, as well as the increased 
duration of stay in ICU in this study population, confirmed the appreciable contribution to the 
risks of patients contracting a positive ESBL producing organism and the their outcomes 
similar to other studies [29]. The importance of comorbid conditions was underlined by the 
statistical significant implication on the risk of death according to the ACCI correlation.  
Having said this, the morbidity calculator does not take in account respiratory distress or 
dependence on ventilatory support.  Consequently, additional care is needed when treating 
these patients. 
 
4.1Prescribing practices before ESBL producing cultures 
Numerous studies underline the impact of antimicrobial exposure and the risk of developing 
an ESBL producing related infection [31,32].  Antibiotic consumption, including the use of 
WKLUGJHQHUDWLRQFHSKDORVSRULQVRWKHUȕ-lactams and fluoroquinolones, are also well-
established risk factors shown to be associated with the acquisition of ESBL producing 
organisms [32].  This is similar to our study where more than 70 percent (77%) of the patients 
UHFHLYHGRWKHUȕ-lactam antibiotics prior to positive ESBL producing organisms being 
cultured. These included cephalosporins, piperacillin/tazobactam and penicillins, which 
might play a role in enhancing an ESBL producing related infection [33].  Other 
antimicrobial exposure includes fluoroquinolones (36%), carbapenems (33%) and 
aminoglycosides (10%).  
 
4.2 Prescribing practices after positive ESBL producing results and clinical outcome 
The majority (64%) of all antibiotics prescribed post positive ESBL producing organisms 
were appropriate according to the sensitivity report. According to Pannell, the simple 
approach to sensitivity analysis, given its ease and transparency, may even be the optimal 
method for the purpose of practical decision making [34]. 
 
Patients who receive appropriate therapy according to the microbiology results showed a 
better clinical outcome than those with inappropriate therapy; however, whilst these results 
were not statistically significant they underline the importance of appropriate prescribing 
practices after positive microbiology results.   
 
Just under half (47%) of the patients who died also received appropriate treatment after 
positive ESBL producing organisms, which underlines the fact that sensitivity and 
PLFURELRORJ\UHVXOWVFDQQRWEHLQWHUSUHWHGZLWKRXWWDNLQJWKHSDWLHQWV¶FR-morbidity into 
consideration. This was also confirmed in a study done by Van Daalen et al [35].  
 
Overall, we believe our findings provide a stimulus to establish an antimicrobial stewardship 
team (ASTs) in this hospital, and likely in other hospitals in South Africa, to reduce 
inappropriate prescribing and dispensing and reduce AMR rates [4]. Coetzee and Brink 
underlined the importance of an antibiotic stewardship team and suggest that restrictive 
measures, even when perceived as punitive measures, may be required to influence future 
antibiotic prescriptions [13].  Similar activities have been seen in other countries to try and 
reduce AMR rates [36-40]. The AST should provide advice to improve and adapt antibiotic 
prescriptions, and to encourage prescribers to adapt their treatment in accordance with local 
sensitivity reports and recommendations, with evidence-based prescribing and dispensing 
seen as a future standard of care [2,41,42]. Prescribing practices can be positively influenced 
by pharmacists through relationship building with prescribers and by leading and driving 
antibiotic stewardship initiatLYHVEXLOGLQJRQWKH6RXWK$IULFDQ¶VJRYHUQPHQWLQLWLDWLYHVWR
reduce AMR rates [4,40].  As part of this, de-escalation should also be systematically 
proposed when clinical and microbiological data allows for this using patient co-morbidities 
to guide suggested therapies.  
 
  
4.3 Limitations 
We are aware that the study followed a retrospective, epidemiological observational 
approach, with some the patient files incomplete.  In addition, the findings were based on the 
data captured by the infection prevention practitioner of the hospital where the study was 
conducted and we did not look at issues of mortality broken down by de-escalation or no de-
escalation.  We are also aware that we used the 27th edition of CLSI for our study analysis 
and not the 28th edition, and that the study was conducted in only one hospital in South 
Africa. However, this is a leading private hospital in South Africa providing guidance to 
others. Consequently, we believe that despite these limitations our findings are robust 
providing direction for the future in this and other hospitals in South Africa. 
 
5. CONCLUSION 
 
The length of ICU stay, ventilatory status and prior exposure to antibiotics were found to be 
significant risk factors associated with ESBL producing E. coli and/or K. pneumoniae 
acquisition status of patients.  Consequently, restricting the use of antibiotics, along with 
implementation of infection control measures, should help control and decrease the spread of 
ESBL producing pathogens. Recommendations to this and other leading hospitals in South 
Africa in light of our findings also include writing and implementing an antibiotic policy in 
the MICU and TICU, taking into consideration the ventilatory status and co-morbid 
conditions of patients to limit antimicrobial exposure. In this study there was no indication if 
the antibiotic was de-escaled to avoid carbapenem use and factors associated with omission 
of de-escalation should be studied further especially if they have an influence on mortality 
rates.  There should also be a strong urge to establish proactive ASTs to monitor these efforts. 
 
There was also no indication if the infections were colonisations or an active infection, which 
is an important part of antimicrobial stewardship.  Consequently, it is recommended that 
future studies of this nature be limited in scope to ensure effective focus and in depth 
evaluations of specific guidelines related to antibiotic prescriptions.  We also believe it is 
important that future researchers undertake a mix of quantitative and qualitative study 
designs, which will allow in-GHSWKUHVHDUFKRIWKHSUHVFULEHUV¶YLHZVZKHQSUHVFULELQJ
antibiotics to better plan for the future.   
 
This hospital has now established a multidisciplinary AST, and is working towards reducing 
irrational prescribing practices in the ICU.   Future research will concentrate on assessing the 
impact of these initiatives including their influence on future clinical outcomes and improved 
management of patients in the ICU. 
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